Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DERM Journey Medical	$7.19 -1.5%	$7.04	$3.54 ▼ $8.25	$170.06M	0.8	91,570 shs	64,122 shs
ENTA Enanta Pharmaceuticals	$7.54 +4.3%	$6.81	$4.09 ▼ $15.92	$154.55M	0.84	280,230 shs	213,585 shs
NXTC NextCure	$4.99 -2.7%	$5.68	$2.69 ▼ $21.48	$13.72M	1.06	11,588 shs	29,253 shs
ODT Odonate Therapeutics		$1.27	$0.85 ▼ $7.10	N/A	N/A	N/A	87,682 shs
RCKT Rocket Pharmaceuticals	$3.04 -9.0%	$3.65	$2.19 ▼ $26.98	$356.66M	0.67	2.32 million shs	4.00 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DERM Journey Medical	+1.39%	+1.11%	+15.69%	+16.80%	+27.40%
ENTA Enanta Pharmaceuticals	+1.97%	+3.58%	+2.55%	+41.76%	-54.30%
NXTC NextCure	+6.43%	-8.69%	-5.32%	+18.36%	-75.71%
ODT Odonate Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
RCKT Rocket Pharmaceuticals	+16.78%	+5.70%	+22.79%	-47.24%	-85.84%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DERM Journey Medical	2.265 of 5 stars	3.5	1.0	0.0	0.0	2.9	1.7	0.6
ENTA Enanta Pharmaceuticals	3.7724 of 5 stars	3.4	1.0	0.0	4.7	2.0	2.5	0.0
NXTC NextCure	4.3729 of 5 stars	3.4	3.0	0.0	4.3	2.5	1.7	1.3
ODT Odonate Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RCKT Rocket Pharmaceuticals	4.8474 of 5 stars	4.2	3.0	0.0	4.7	1.8	4.2	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DERM Journey Medical	3.00	Buy	$9.50	32.13% Upside
ENTA Enanta Pharmaceuticals	2.80	Moderate Buy	$18.00	138.73% Upside
NXTC NextCure	2.75	Moderate Buy	$33.00	561.32% Upside
ODT Odonate Therapeutics	0.00	N/A	N/A	N/A
RCKT Rocket Pharmaceuticals	2.41	Hold	$18.60	511.84% Upside

Current Analyst Ratings Breakdown

Latest NXTC, DERM, ODT, RCKT, and ENTA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/15/2025	NXTC NextCure	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Overweight ➝ Overweight	$36.00 ➝ $15.00
7/8/2025	NXTC NextCure	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
7/1/2025	NXTC NextCure	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$36.00
6/17/2025	RCKT Rocket Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $5.00
6/3/2025	ENTA Enanta Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$23.00 ➝ $24.00
6/3/2025	RCKT Rocket Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$34.00 ➝ $11.00
5/30/2025	RCKT Rocket Pharmaceuticals	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ In-Line	$5.00
5/28/2025	RCKT Rocket Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/28/2025	RCKT Rocket Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Neutral
5/28/2025	RCKT Rocket Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$32.00 ➝ $9.00
5/28/2025	RCKT Rocket Pharmaceuticals	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$30.00 ➝ $8.00

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DERM Journey Medical	$56.13M	2.98	N/A	N/A	$0.91 per share	7.90
ENTA Enanta Pharmaceuticals	$67.64M	2.38	N/A	N/A	$6.08 per share	1.24
NXTC NextCure	N/A	N/A	N/A	N/A	$28.06 per share	N/A
ODT Odonate Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	$5.08 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DERM Journey Medical	-$14.67M	-$0.39	N/A	N/A	-14.76%	-52.03%	-11.28%	8/11/2025 (Estimated)
ENTA Enanta Pharmaceuticals	-$116.04M	-$4.54	N/A	N/A	-149.57%	-79.83%	-26.65%	8/4/2025 (Estimated)
NXTC NextCure	-$55.65M	-$21.13	N/A	N/A	N/A	-70.16%	-58.10%	7/30/2025 (Estimated)
ODT Odonate Therapeutics	-$126.35M	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RCKT Rocket Pharmaceuticals	-$258.75M	-$2.63	N/A	N/A	N/A	-64.92%	-56.13%	8/4/2025 (Estimated)

Latest NXTC, DERM, ODT, RCKT, and ENTA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	DERM Journey Medical	-$0.06	N/A	N/A	N/A	$14.93 million	N/A
8/7/2025	Q2 2025	NXTC NextCure	-$0.39	N/A	N/A	N/A	N/A	N/A
8/4/2025	Q3 2025	ENTA Enanta Pharmaceuticals	-$1.10	N/A	N/A	N/A	$16.21 million	N/A
8/4/2025	Q2 2025	RCKT Rocket Pharmaceuticals	-$0.57	N/A	N/A	N/A	$4.36 million	N/A
5/14/2025	Q1 2025	DERM Journey Medical	-$0.24	-$0.18	+$0.06	-$0.18	$12.05 million	$13.14 million
5/13/2025	Q1 2025	RCKT Rocket Pharmaceuticals	-$0.58	-$0.56	+$0.02	N/A	N/A	N/A
5/12/2025	Q2 2025	ENTA Enanta Pharmaceuticals	-$1.04	-$1.06	-$0.02	-$1.06	$15.96 million	$14.93 million
5/5/2025	Q1 2025	RCKT Rocket Pharmaceuticals	-$0.59	-$0.56	+$0.03	-$0.56	$0.80 million	N/A
5/1/2025	Q1 2025	NXTC NextCure	-$4.80	-$4.68	+$0.12	-$0.39	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DERM Journey Medical	N/A	N/A	N/A	N/A	N/A
ENTA Enanta Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
NXTC NextCure	N/A	N/A	N/A	N/A	N/A
ODT Odonate Therapeutics	N/A	N/A	N/A	N/A	N/A
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DERM Journey Medical	1.07	1.34	1.03
ENTA Enanta Pharmaceuticals	N/A	5.29	5.29
NXTC NextCure	N/A	10.26	10.26
ODT Odonate Therapeutics	N/A	N/A	N/A
RCKT Rocket Pharmaceuticals	0.05	9.19	9.19

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DERM Journey Medical	7.25%
ENTA Enanta Pharmaceuticals	94.99%
NXTC NextCure	42.65%
ODT Odonate Therapeutics	N/A
RCKT Rocket Pharmaceuticals	98.39%

Insider Ownership

Company	Insider Ownership
DERM Journey Medical	15.03%
ENTA Enanta Pharmaceuticals	13.89%
NXTC NextCure	17.90%
ODT Odonate Therapeutics	48.90%
RCKT Rocket Pharmaceuticals	24.76%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DERM Journey Medical	90	23.30 million	19.80 million	N/A
ENTA Enanta Pharmaceuticals	160	21.38 million	18.41 million	Optionable
NXTC NextCure	90	2.68 million	2.20 million	Optionable
ODT Odonate Therapeutics	145	28.53 million	14.58 million	Not Optionable
RCKT Rocket Pharmaceuticals	240	106.79 million	80.35 million	Optionable

NXTC, DERM, ODT, RCKT, and ENTA Headlines

Recent News About These Companies

RCKT Stock Up on FDA's RMAT Tag to Gene Therapy for Heart Failure

July 18 at 12:31 PM | zacks.com

Deadline Alert: Rocket Pharmaceuticals, Inc. ...

July 18 at 12:08 PM | gurufocus.com

Class Action Filed Against Rocket Pharmaceuticals, Inc. ...

July 18 at 9:31 AM | gurufocus.com

Class Action Filed Against Rocket Pharmaceuticals, Inc. (RCKT) Seeking Recovery for Investors - Contact Levi & Korsinsky

July 18 at 8:45 AM | prnewswire.com

RCKT Investors Have Opportunity to Lead Rocket Pharmaceuticals, Inc. Securities Fraud Lawsuit

July 17 at 6:05 PM | prnewswire.com

Rocket Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before August 11, 2025 to Discuss Your Rights – RCKT

July 17 at 4:15 PM | globenewswire.com

RCKT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

July 17 at 4:00 PM | globenewswire.com

FDA Clinical Hold on RP-A501 Trial Triggers Rocket Pharmaceuticals (RCKT) Stock Plunge and Class Action– Hagens Berman

July 17 at 3:07 PM | globenewswire.com

Rocket Pharmaceuticals gets FDA RMAT status for heart disorder therapy

July 17 at 1:42 PM | msn.com

Rocket Pharmaceuticals stock surges after FDA grants key designation

July 17 at 1:42 PM | investing.com

Rocket Pharmaceuticals Shares Jump After FDA Grants Accelerated Review Status to Gene Therapy

July 17 at 1:42 PM | msn.com

Rocket Pharmaceuticals, Inc. (RCKT) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

July 17 at 12:00 PM | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Rocket Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - RCKT

July 17 at 10:00 AM | prnewswire.com

Rocket Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - RCKT

July 17 at 9:00 AM | prnewswire.com

NASDAQ: RCKT INVESTOR ALERT: Berger Montague Advises Rocket Pharmaceuticals (RCKT) Investors of August 11, 2025 Deadline

July 17 at 8:36 AM | globenewswire.com

Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-A601 Gene Therapy for PKP2-Arrhythmogenic Cardiomyopathy

July 17 at 7:00 AM | businesswire.com

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Receives Average Rating of "Hold" from Brokerages

July 17 at 2:46 AM | marketbeat.com

B2B Rocket joins publicly traded tech powerhouse in move to scale smarter and faster

July 16 at 5:38 PM | manilatimes.netM

Virgin Islands Students Complete Elite NASA-Style Training at U.S. Space & Rocket Center

July 16 at 5:38 PM | viconsortium.comV

Army Unit in Hawaii Receives Long-range Rocket Artillery for Pacific Operations

July 16 at 5:38 PM | news.usni.orgN

Rocket Pharmaceuticals, Inc. (RCKT) Securities Fraud Class Action Lawsuit Pending: Contact Wolf Haldenstein Before August 11, 2025 to Discuss Your Rights

July 16 at 4:44 PM | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NXTC, DERM, ODT, RCKT, and ENTA Company Descriptions

Journey Medical NASDAQ:DERM

$7.19 -0.11 (-1.51%)

Closing price 04:00 PM Eastern

Extended Trading

$7.20 +0.00 (+0.07%)

As of 04:06 PM Eastern

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.

Enanta Pharmaceuticals NASDAQ:ENTA

$7.54 +0.31 (+4.29%)

Closing price 04:00 PM Eastern

Extended Trading

$7.40 -0.14 (-1.84%)

As of 04:31 PM Eastern

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

NextCure NASDAQ:NXTC

$4.99 -0.14 (-2.73%)

Closing price 04:00 PM Eastern

Extended Trading

$5.05 +0.06 (+1.20%)

As of 07:16 PM Eastern

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.

Odonate Therapeutics NASDAQ:ODT

Odonate Therapeutics is a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer. Our initial focus is on the development of tesetaxel, a novel chemotherapy agent that belongs to a class of drugs known as taxanes, which are widely used in the treatment of cancer. Tesetaxel has several potential therapeutic advantages over currently available taxanes, including: oral administration with a low pill burden and a patient-friendly dosing regimen; a formulation that does not contain solubilizing agents that are known to cause hypersensitivity (allergic) reactions; and improved activity against chemotherapy-resistant tumors. Tesetaxel has been generally well tolerated in clinical studies and has demonstrated robust single-agent antitumor activity in two Phase 2 studies in patients with locally advanced or metastatic breast cancer (''MBC'').

Rocket Pharmaceuticals NASDAQ:RCKT

$3.04 -0.30 (-8.98%)

Closing price 04:00 PM Eastern

Extended Trading

$3.08 +0.04 (+1.32%)

As of 07:53 PM Eastern

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time